Wed.Dec 25, 2024

article thumbnail

Protection of Personal Data in European Medicine Regulation

PharmaTech

Revised guidelines published by EMA and HMA update the rules on identification of commercially confidential information and personal data used in marketing authorization applications.

article thumbnail

Top 4 Cold Chain Articles of 2024

Pharmaceutical Commerce

The latest in container tech and temperature-monitoring truly powered the content.

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Prasinezumab Misses Primary Endpoint in Roche’s Phase IIb Study, but Has Potential in Treating Early Stage Parkinson’s Disease

PharmaTech

Results from a Phase IIb study missed the primary endpoint by failing to achieve statistical significance.

52
article thumbnail

The Impact of Regulatory Policy on Telehealth Innovation

PharmExec

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that telehealth companies face in 2025.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

VMT-01 by Perspective Therapeutics for Metastatic Melanoma: Likelihood of Approval

Pharmaceutical Technology

VMT-01 is under clinical development by Perspective Therapeutics and currently in Phase II for Metastatic Melanoma.

40
article thumbnail

2024’s Executive Profiles

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

More Trending

article thumbnail

Optimizing Infusion Chair Time for Oncology Trials: Follow-Up Study

Pharmacy Times

This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.

article thumbnail

Dexamethasone sodium phosphate SR by Taiwan Liposome for Osteoarthritis Pain: Likelihood of Approval

Pharmaceutical Technology

Dexamethasone sodium phosphate SR is under clinical development by Taiwan Liposome and currently in Phase III for Osteoarthritis Pain.

40
article thumbnail

Treatment Goals for Patients With PBC

Pharmacy Times

Panelists discuss how the main treatment goals for patients with primary biliary cholangitis (PBC) include improving liver biochemistry, preventing disease progression to cirrhosis, managing symptoms, and enhancing overall quality of life through regular monitoring and appropriate therapeutic interventions.

article thumbnail

Fosravuconazole by Eisai for Tinea Pedis (Athlete Foot): Likelihood of Approval

Pharmaceutical Technology

Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot).

40
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Exploring Second-Line Treatments for PBC

Pharmacy Times

Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.

article thumbnail

EXO-CD24 by Nano24med for Acute Respiratory Distress Syndrome: Likelihood of Approval

Pharmaceutical Technology

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

40
article thumbnail

Gecacitinib Demonstrates Safety, Efficacy Over Hydroxyurea in Patients With Myelofibrosis and Anemia

Pharmacy Times

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

Safety 20
article thumbnail

AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger’s Disease): Likelihood of Approval

Pharmaceutical Technology

AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease).

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Follow Essential Steps When Reporting Medication Incidents

Pharmacy Times

Proper reporting of errors and near misses helps maintain compliance and improve patient safety.

Medical 20
article thumbnail

Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval

Pharmaceutical Technology

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

article thumbnail

Gamma-PN by GPN Vaccines for Streptococcal Pneumonia: Likelihood of Approval

Pharmaceutical Technology

Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia.

40
article thumbnail

ACTUS-101 by Asklepios BioPharmaceutical for Pompe Disease: Likelihood of Approval

Pharmaceutical Technology

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

40
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

NB-4746 by Nura Bio for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Pharmaceutical Technology

NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis.

40